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Our aim was to investigate the association between behavioral symptoms of agitation,
disinhibition, irritability, elation, and aberrant motor behavior to frontal brain volumes in
a cohort with various neurodegenerative diseases. A total of 121 patients with mild
cognitive impairment (MCI, n = 58), Alzheimer’s disease (AD, n = 45) and behavioral
variant frontotemporal dementia (bvFTD, n = 18) were evaluated with a Neuropsychiatric
Inventory (NPI). A T1-weightedMRI scan was acquired for each participant and quantified
with a multi-atlas segmentation method. The volumetric MRI measures of the frontal
lobes were associated with neuropsychiatric symptom scores with a linear model. In the
regression model, we included CDR score and TMT B time as covariates to account
for cognitive and executive functions. The brain volumes were corrected for age, gender
and head size. The total behavioral symptom score of the five symptoms of interest was
negatively associated with the volume of the subcallosal area (β = −0.32, p = 0.002).
High disinhibition scores were associated with reduced volume in the gyrus rectus (β =
−0.30, p = 0.002), medial frontal cortex (β = −0.30, p = 0.002), superior frontal gyrus
(β = −0.28, p = 0.003), inferior frontal gyrus (β = −0.28, p = 0.005) and subcallosal
area (β = −0.28, p = 0.005). Elation scores were associated with reduced volumes of
the medial orbital gyrus (β = −0.30, p = 0.002) and inferior frontal gyrus (β = −0.28, p =
0.004). Aberrant motor behavior was associated with atrophy of frontal pole (β = −0.29,
p = 0.005) and the subcallosal area (β = −0.39, p < 0.001). No significant associations
with frontal brain volumes were found for agitation and irritability. We conclude that the
subcallosal area may be common neuroanatomical area for behavioral symptoms in
neurodegenerative diseases, and it appears to be independent of disease etiology.
Keywords: magnetic resonance imaging, mild cognitive impairment, Alzheimer’s disease, frontotemporal
dementia, behavioral symptoms
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INTRODUCTION
Neurodegenerative diseases exhibit various symptoms affecting
patients’ behavior and personality. Behavioral symptoms such
as agitation, disinhibition, irritability, elation, and aberrant
motor behavior have a great effect on patients’ social relations,
caregiver burden, and quality of life. Some symptoms are more
characteristic for specific diseases, but there is overlapping
of behavioral symptoms between different diseases. Various
behavioral symptoms may be present even in the earliest
clinical stages of these diseases and the detection of these
symptoms can be valuable for diagnostic purposes. Typical
behavioral symptoms in the early stage of Alzheimer’s disease
(AD) are apathy, agitation, irritability, anxiety, and depression
(1–4). Considering bvFTD, typical behavioral symptoms are
disinhibition, agitation, apathy, loss of empathy, aberrant
motor behavior and preservative compulsive behavior (1,
5, 6). Disinhibition, apathy, emotional bluntness, aberrant
motor behavior, stereotypical behaviors and eating abnormalities
are more characteristic to bvFTD and have been found to
discriminate bvFTD from AD (1, 6–8). Behavioral symptoms are
also interrelated with dementia severity in AD. Higher agitation,
apathy, disinhibition, irritability, and aberrant motor behavior
scores are associated with increased dementia severity in AD (1,
9). In bvFTD, the severity of behavioral symptoms is higher than
in AD, yet no difference in severity of behavioral disturbances is
observed (10). Behavioral symptoms may also be present in cases
with mild cognitive impairment (MCI). Especially symptoms
such as apathy, agitation, anxiety, irritability, and depression, are
more prevalent in subjects with MCI compared to healthy people
(11, 12).
Different neurodegenerative disorders present different
pattern of brain atrophy compared to each other. The medial
temporal atrophy is typical for AD (13, 14), while anterior
temporal and/or frontal lobes, the insula and anterior cingulate
cortex are affected in bvFTD (15–19). However, there are
variance of the pattern of atrophy within both these diagnostic
entities. For instance, bvFTD may present different type of
atrophy depending from underlying genetic background (20–
24). Even though the patterns of atrophy differ, there are also
some overlap of brain areas that are affected in these diseases.
Given that also behavioral symptoms overlap in different disease
etiologies, it supports the idea that damage in some brain areas or
networks are associated with specific types of behavioral changes.
Detection of neuroanatomical changes associated with these
behavioral changes could improve early diagnostic of dementing
diseases. Similar idea has been presented for mental disorders by
the Research Domain Criteria (RDoC), suggesting that mental
disorders are disorders of brain circuits, and specific behavioral
signs and symptoms can be explained with neuroimaging and
other brain functional quantification methods in vivo (25).
In some studies, the association between a specific behavioral
symptom and cortical areas has been identified in AD and
Abbreviations: AD, Alzheimer’s Disease; bvFTD, Behavioral variant
frontotemporal dementia; MCI, Mild cognitive impairment; NPI,
Neuropsychiatric inventory.
bvFTD. Disinhibition has been associated with gray matter
atrophy in the orbitofrontal cortex (26, 27). Agitation has
been associated with atrophy in the inferior frontal cortex,
insula and anterior cingulate cortex (28, 29) and aberrant
motor behavior with decreased volume in anterior cingulate
gyrus and inferior frontal cortex (27, 28). Similar findings have
been also found in other neurodegenerative conditions and
also in healthy people (30–32). However, it remains unclear
whether these neuroanatomical correlates are disease specific or
is there common foci of neural damage associating to behavioral
symptoms independently of clinical diagnosis.
The aim of this study was to evaluate common
neuroanatomical associations in the frontal area for behavioral
symptoms in a cohort of patients with MCI, AD, and bvFTD,
irrespective of underlying neurodegenerative disorder. Our
hypothesis is, that behavioral symptoms could be driven by
common neuroanatomical correlates, regardless of clinical
diagnosis. If there were such common associations for behavioral
symptoms, this information could be of great value when
targeting treatments for individual patients. Contrary to
previous studies, our data consist of patients with different
neurodegenerative diseases at varying clinical stages allowing
us to locate regions of interest in neural networks that associate
with behavioral symptoms, regardless of the underlying disease
etiology or pathology.
MATERIALS AND METHODS
Participants
We examined a total of 121 subjects including 58 patients
with a diagnosis of MCI, 45 AD and 18 bvFTD. The study
population consisted of 92 subjects from Kuopio, Finland, and
29 subjects from Sheffield, United Kingdom (Table 1). The
data are part of the VPH-DARE@IT project. The diagnoses of
neurodegenerative diseases were formulated by an experienced
neurologist specialized in memory disorders according to
standard clinical criteria (16, 33–36). We included only patients
with an appropriate T1-weighted MRI scan who had a correctly
completed Neuropsychiatric Inventory (NPI). Mini-Mental State
Examination (MMSE) scores, Clinical Demenita Rating (CDR)
scores and Trail Making B test time were also determined.
The ethics committee of the Northern Savonia Hospital
District for the Kuopio cohort and the Yorkshire and Humber
Regional Ethics Committee (Ref No: 12/YH/0474) for the
Sheffield cohort approved the research protocol in accordance
with the principles of the Declaration of Helsinki. Written
informed consent was obtained from all participants prior
to enrollment.
All included patients were 50–85 years old. Inclusion criteria
for the MCI patients were set as follows: MCI diagnosis
as evidenced by the following: referral because of cognitive
impairments and diagnosis of amnestic or non-amnestic MCI
(33, 34). AD patients were included if they met the diagnostic
criteria for probable AD according to NINCDS-ADRDA
Alzheimer’s criteria (36) or the diagnosis of prodromal AD
according to Dubois et al. (35). bvFTD patients were included
if they met the Neary et al. clinical diagnostic criteria for FTD
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TABLE 1 | Demographic and clinical data according to clinical diagnosis.
Total MCI AD bvFTD p
N (%) 121 (100%) 58 (48%) 45 (37%) 18 (15%)
Gender, female, %
(N)
53% (64) 57% (33) 47% (21) 57% (10) 0.6
Age, mean (SD) 68.2 (9.4) 69.4 (9.0) 68.8 (9.6) 62.6 (8.5) 0.02
Education years,
mean (SD)
11.3 (3.5) 11.4 (3.7) 11.4 (3.6) 10.6 (2.6) 0.7
MMSE score, mean
(SD)
23.5 (4.8) 26.3 (2.5) 21.5 (4.9) 19.8 (5.4) <0.001
CDR score, mean
(SD)
0.7 (0.5) 0.48 (0.1) 1.0 (0.6) 0.8 (0.6) <0.001
TMT B time, sec,
mean (SD)
242 (159) 194 (99) 311 (215) 240 (83) 0.001
Total NPI score,
mean (SD)
8.8 (12.5) 7.2 (11.4) 9.4 (12.5) 12.7 (15.5) 0.3
Statistical significance between groups was assessed with ANOVA and chi square test.
(16). The recruiting of study population was initiated before the
establishment of the international consensus criteria for behavior
variant frontotemporal dementia (15), thus the consensus criteria
by Neary and colleagues were used in the recruitment. However,
we retrospectively evaluated the bvFTD patient’s data and all
subjects fulfilled the criteria for at least clinical probable bvFTD,
presenting significant functional decline and positive imaging
findings (15).
Patients were excluded if they had obvious brain, systemic
or psychiatric disorders that could possibly affect cognitive
functions such as stroke, severe depression or endocrine
disorders. Also, MCI patients were excluded if they met the
diagnostic criteria of dementia according to DSM-IV at baseline.
Neuropsychiatric Evaluation
Behavioral symptoms were evaluated using the NPI (37). The
NPI is a structured interview administered to patients’ caregivers.
It consists of 10 or 12 separate items assessing neuropsychiatric
disturbances common in dementia, including delusions,
hallucinations, agitation/aggression, depression/dysphoria,
anxiety, elation/euphoria, apathy/indifference, disinhibition,
irritability/lability, aberrant motor behavior, nighttime behaviors
and appetite/eating disorders. In this study, we used the
original 10 items and further grouped those symptoms into
three categories, behavioral, affective and psychotic symptoms
according to a hierarchical clustering of the NPI items (Figure 1).
The clustering of our cohort was similar to the results from a
factorial analysis performed with a larger dementia cohort (38).
We performed a preliminary analysis for the neuroanatomical
correlates with all neuropsychiatric clusters. This analysis
revealed significant correlations with frontal lobe structures only
with behavioral symptoms, thus we focused our more specific
analyses only on behavioral symptoms and excluded affective
and psychotic items (results of correlation analysis for affective
and psychotic symptoms in Supplementary Figure 1). Eating
abnormalities and nighttime behaviors were also excluded from
analyses, since they are not part of the core NPI questionnaire,
and these items include several types or positive and negative
symptoms (e.g., hyperorality vs. lack of appetite). The clustering
resulted in behavioral symptoms including agitation, irritability,
disinhibition, elation, and aberrant motor behavior. The
frequency and severity of each item were rated. Composite scores
for each individual neuropsychiatric symptom were calculated
by multiplying the frequency score (1–4, occasionally-very often)
by severity score (1–3, mild-difficult), making 12 the highest
possible score for each item. A behavioral symptoms total score
was calculated by adding up the composite scores of agitation,
irritability, disinhibition, elation and aberrant motor behavior,
making the maximum score 5∗12= 60.
MRI Analysis
MRI scans were acquired on a Phillips Achieva 3T scanner
in Kuopio and Phillips Ingenia 3T scanner in Sheffield using
a shared image acquisition protocol. Gradient echo 3D T1-
weighted images were acquired sagittally with the following
parameters: voxel size: 0.94 × 0.94 × 1.00mm; repetition time:
8.2ms; echo delay time: 3.8ms; field of view: 256mm;matrix size:
256× 256× 170.
Image segmentation was performed using the commercial
cNeuro R© cMRI image quantification tool (Combinostics,
Tampere, Finland). The tool segments images to 133 areas by
using a multi-atlas segmentation framework (39). The method
consists of the following steps: (1) atlas selection is performed,
(2) a probabilistic atlas is generated by registering non-rigidly
the selected atlases to the patient image and (3) expectation
maximization classification is applied for producing the final
segmentation (39). The volumes were normalized first for head
size (40) and then for age and gender (41).
We focused our analyses to the frontal lobes and excluded
other areas in order to maintain sufficient statistical power and
due to findings of existing literature. A total of 11 different brain
areas of the frontal lobe was selected and the total volumes of
the frontal lobes to be used in the analyses included anterior,
posterior, lateral and medial orbital gyrus, gyrus rectus, medial
frontal cortex, frontal pole, superior frontal gyrus, middle frontal
gyrus, inferior frontal gyrus, and the subcallosal area. The volume
of the inferior frontal gyrus was calculated by adding three
separate segments together: opercular, triangular, and orbital part
of the inferior frontal gyrus. The rest of the areas were analyzed
as they were segmented by the multi-atlas segmentation method.
Any brain areas outside the frontal lobes were excluded.
Statistical Analysis
The NPI items were grouped with hierarchical clustering using
between-groups linkage and Pearson’s correlation as the distance
between items. The demographic and clinical data between
diagnostic groups were analyzed with one-way ANOVA and chi-
square tests. The initial correlation analysis of all segmented brain
volumes and neuropsychiatric symptoms was done with two-
tailed Pearson’s correlation. Further analyses of the association
between behavioral symptom scores and frontal brain volumes
was tested with a linear regression model using CDR (Clinical
Dementia Rating) score and TMT-B (Trail-Making Test, B)
time as confounders, to control the effect of subjects’ cognitive
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FIGURE 1 | Hierarchical clustering of the NPI symptoms shown as a dendrogram. The clustering was done with between-groups linkage using Pearson’s correlation
as the distance between the NPI items.
state and executive functioning. We also examined differences
in volumetric brain measures in different groups with one-way
ANOVA, using Tukey’s post hoc analysis. We chose to only
discuss results with p ≤ 0.005 as significant due to multiple
testing. The analyses were performed with IBM SPSS Statistics,
version 25.
RESULTS
The bvFTD group was on average 6 years younger compared to
the AD group and 7 years younger than the MCI group. The
MMSE score was higher in the MCI group compared to the
AD and bvFTD groups. There were no significant differences in
the degree of education, gender distribution or total NPI scores
among the three groups. The demographic data are presented in
Table 1.
The frequency of behavioral symptoms and the composite NPI
scores according to clinical diagnoses are shown in Table 2. The
composite scores (frequency∗severity) in all studied behavioral
symptom categories were higher in patients with bvFTD.
Disinhibition scores were significantly higher in the bvFTD
group compared to the AD and MCI groups. Aberrant motor
behavior and elation scores were also higher in bvFTD compared
to MCI. Irritability was the most frequent symptom in the whole
group (33%) as well as in patients with AD (38%) andMCI (31%).
Disinhibition and aberrant motor behavior were most common
in patients with bvFTD (33 and 28%, respectively). However,
there were no statistical differences in the frequency of any of the
behavioral symptoms among the three groups.
One-way ANOVA and Tukey’s post hoc analysis showed
that the volume of the subcallosal area did not differ among
the three diagnostic groups. All other frontal lobe volumes
showed statistically significant differences among the three
groups (Table 3). The comparison of brain volumes between
different diagnostic groups is shown in Figure 2. Compared to
MCI, the bvFTD group showed extensive atrophy in frontal
cortex, striatum and temporal lobes, and also enlarged lateral
ventricles. Marked parietal and also temporal atrophy was
detected in AD compared to MCI cases. The comparison
between AD and bvFTD revealed prominent medial frontal
and orbitofrontal atrophy in bvFTD group, while none of
evaluated brain areas was smaller in the AD group compared
to bvFTD.
We analyzed the association between NPI behavioral
symptom total scores and frontal volumes in all patients using
the CDR score and TMT-B time confounders (Table 4). There
was significant association between the total behavioral symptom
score of these five symptoms and the volume of the subcallosal
area (β = − 0.32, p = 0.002) (Figure 3). Disinhibition scores
were associated with reduced volumes in the gyrus rectus (β
= − 0.30, p = 0.002), medial frontal cortex (β = − 0.30, p =
0.002), superior frontal gyrus (β = −0.28, p = 0.004), inferior
frontal gyrus (β = −0.28, p = 0.005) and in the subcallosal area
(β = − 0.28, p = 0.005). Aberrant motor behavior scores were
associated with reduced volume of frontal pole (β = −0.29, p
= 0.005) the subcallosal area (β = − 0.39, p < 0.001). Elation
was associated with the medial orbital gyrus (β = −0.30, p
= 0.002) and inferior frontal gyrus (β = −0.28, p = 0.004).
There was no association between agitation and irritability
with any focal or gross frontal volumes. Visualizations of the
correlations between behavioral symptoms and brain areas are
shown in Figure 4.
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TABLE 2 | Total scores and frequency of NPI behavioral symptoms according to clinical diagnosis.
Diagnosis Behavioral symptoms total Agitation Elation Disinhibition Irritability Aberrant motor behavior
MCI Score mean (SD) 1.7 (3.2)* 0.4 (1.1) 0.1 (0.4)* 0.2 (0.4)* 0.8 (1.4) 0.3 (1.2)*
Frequency 41 % 17 % 9 % 14 % 31 % 10 %
AD Score mean (SD) 3.2 (5.5) 0.8 (1.7) 0.4 (1.2) 0.4 (1.2)* 1.1 (2.0) 0.6 (1.4)
Frequency 53 % 31 % 11 % 18 % 38 % 20 %
bvFTD Score mean (SD) 6.3 (10.7)* 1.1 (2.2) 0.9 (2.9)* 1.4 (2.6)* 1.2 (2.6) 1.7 (2.9)*
Frequency 44 % 28 % 17 % 33 % 28 % 28 %
Total Score mean (SD) 3.0 (5.9) 0.6 (1.5) 0.3 (1.4) 0.4 (1.3) 1.0 (1.8) 0.6 (1.7)
Frequency 46 % 24 % 11 % 18 % 33 % 17 %
P-value 0.01 0.18 0.08 <0.01 0.51 0.01
Frequency was calculated as a dichotomous variable, based on whether the patient did have symptoms of any severity or did not, and is presented as percentage of the population.
The mean values of symptom total scores (frequency*severity) are presented separately for each clinical diagnosis group and for the whole cohort. Statistical significance of symptom
scores were estimated with one-way ANOVA using Tukey’s post hoc analysis.
*Statistically significant difference (p ≤ 0.05) in between MCI/AD and bvFTD.
TABLE 3 | Comparison of brain volumes of the frontal lobes based on clinical diagnoses.
Combined volumes of R&L hemispheres, cm3 Total MCI AD bvFTD p-value, all groups p-value, AD vs. bvFTD
Anterior orbital gyrus, mean (SD) 3.4 (0.6) 3.6 (0.6) 3.4 (0.6) 3.0 (0.6) 0.001 0.020
Posterior orbital gyrus, mean (SD) 5.0 (0.7) 5.2 (0.6) 5.0 (0.6) 4.3 (0.8) <0.001 <0.001
Lateral orbital gyrus, mean (SD) 3.1 (0.6) 3.4 (0.5) 3.0 (0.5) 2.6 (0.6) <0.001 0.006
Medial orbital gyrus, mean (SD) 7.3 (0.9) 7.6 (0.6) 7.4 (0.8) 6.4 (1.1) <0.001 <0.001
Gyrus rectus, mean (SD) 2.9 (0.5) 3.0 (0.4) 2.9 (0.4) 2.4 (0.5) <0.001 <0.001
Medial frontal cortex, mean (SD) 2.5 (0.5) 2.7 (0.4) 2.5 (0.5) 1.9 (0.5) <0.001 <0.001
Frontal pole, mean (SD) 6.0 (0.8) 6.2 (0.6) 6.0 (0.7) 5.3 (1.1) <0.001 0.008
Superior frontal gyrus, mean (SD) 24.8 (2.8) 25.9 (2.2) 24.3 (2.2) 22.5 (3.7) <0.001 0.030
Middle frontal gyrus, mean (SD) 31.8 (4.0) 33.2 (2.7) 31.4 (4.0) 28.1 (5.2) <0.001 0.004
Inferior frontal gyrus, mean (SD) 13.1 (1.7) 13.7 (1.6) 13.0 (1.4) 11.5 (2.0) <0.001 0.002
Subcallosal area, mean (SD) 2.6 (0.4) 2.6 (0.3) 2.6 (0.4) 2.4 (0.4) 0.145 0.160
Frontal lobe, mean (SD) 184 (17) 191 (12) 183 (15) 163 (21) <0.001 <0.001
The values represent combined right and left hemisphere volumes mean (SD) values of specific areas (cm3 ). The volumes were corrected for age, sex and head size. All frontal areas
except the subcallosal area (p = 0.145) showed a statistically significant difference between groups. Statistical significance was assessed with one-way ANOVA in addition with Tukey’s
post hoc analysis.
DISCUSSION
We evaluated the behavioral and frontal volume associations in
a cohort of patients at several clinical stages and with different
etiologies of neurodegenerative diseases. As expected, frontal
lobe volumes were the most preserved in MCI and the most
reduced in bvFTD. Of separate frontal volumes, smaller volumes
in the subcallosal area were associated with higher disinhibition
and aberrantmotor behavior scores, as well as the total behavioral
symptoms score. Higher elation scores also showed a suggestive
association with lower subcallosal volume, however not reaching
statistical significance. There was no difference in the volume
of the subcallosal area among the three groups, emphasizing
its correlations to behavioral symptoms being independent of
underlying disease etiology and stage of cognitive impairment
(Table 3).
In addition to the subcallosal area, higher disinhibition scores
were associated with decreased volume of ventromedial and
lateral prefrontal structures, more specifically the gyrus rectus,
medial frontal cortex and superior and inferior frontal gyrus.
Decreased volumes of these areas have also been associated with
disinhibited behavior in bvFTD and AD patients (27, 28, 30, 32,
42). It has also been postulated that both disinhibition and apathy
associate with orbitofrontal and medial frontal cortices (43).
However, analyses did not show any association between apathy
and analyzed frontal lobe volumes (Supplementary Figure 1).
Taken together previous and our findings it can be assumed
that the symptoms of aberrant motor behavior and disinhibition
are strongly associated with damage to the subcallosal area, the
end-point of the uncinate fasciculus.
To our knowledge there is no previous work assessing
the neural correlates of elation/euphoria in neurodegenerative
diseases. However, there is one study evaluating association
between sensitivity to drug reward (measured as euphoria)
and functional brain correlates in healthy people. This study
suggested reduced activity in the middle frontal gyrus and
poor inhibitory control to be associated with greater drug
reward experienced as euphoria (44). Our data showed an
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FIGURE 2 | Group comparison of brain structure volumes of different diagnostic groups. Top row illustrates the comparison between bvFTD and MCI groups. The
bvFTD group shows frontal and temporal atrophy and also reduced volume of deep gray matter structures. The middle row shows AD group’s temporal and parietal
atrophy compared to the MCI group. The lowest row shows the bvFTD group having reduced orbitofrontal, medial frontal and thalamic volumes compared to AD. The
AD group showed no volume reduction compared to the bvFTD group. Comparison was done with two-tailed t-test and only significant areas of p ≤ 0.001
are highlighted.
association between elation and inferior frontal gyrus and medial
orbital gyrus. We suggest that the dysfunction/atrophy of lateral
prefrontal cortex might be associated with elation with coexisting
poor inhibition in patients with dementia.
The subcallosal area is a small area located in the medial
frontal cortex below the genu of the corpus callosum and anterior
cingulate gyrus, caudal to the gyrus rectus. This area is located
in the path of the uncinate fasciculus, a bilateral white matter
tract connecting the orbitofrontal cortex and the temporal lobe.
The fibers of the uncinate fasciculus connect the amygdala
and the uncus to the subcallosal area (45). Decreased volumes
in the subcallosal area have been previously associated with
disinhibition (27, 42). Also, reduced integrity of the uncinate
fasciculus has been detected in bvFTD, AD and psychiatric
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TABLE 4 | Standardized regression coefficients (β) from the linear regression model of frontal volumes and behavioral symptoms.
Behavioral symptoms total Agitation Disinhibition Elation Irritability Aberrant motor behavior
β β β β β β
Anterior orbital gyrus 0.091 0.133 0.072 −0.040 0.160 −0.005
Posterior orbital gyrus −0.089 −0.015 −0.167 −0.146 0.087 −0.150
Lateral orbital gyrus −0.061 0.063 −0.235 −0.206 0.155 −0.025
Medial orbital gyrus −0.204 0.043 −0.257* −0.302** −0.025 −0.186
Gyrus rectus −0.193 −0.092 −0.301** −0.230 −0.024 −0.124
Medial frontal cortex −0.164 −0.031 −0.302** −0.248* 0.020 −0.107
Frontal pole −0.194 0.089 −0.171 −0.233 −0.044 −0.292**
Superior frontal gyrus −0.222 −0.060 −0.277** −0.237 −0.089 −0.205
Middle frontal gyrus −0.009 0.098 −0.123 −0.101 0.188 −0.164
Inferior frontal gyrus −0.214 −0.120 −0.276** −0.279** −0.073 −0.088
Subcallosal area −0.317** −0.140 −0.282** −0.262* −0.115 −0.387**
Frontal lobe −0.139 0.014 −0.265* −0.233* 0.064 −0.163
The behavioral symptoms column represents the total score of the five individual behavioral symptoms (agitation, disinhibition, elation, irritability and aberrant motor behavior) and
combined score of these five symptoms. The models are corrected for CDR score and TMT-B time. The volumes have been pre-corrected for age, gender and head size. Results with
statistical significance of p ≤ 0.005 are in bold. *p ≤ 0.01; **p ≤ 0.005.
FIGURE 3 | Association of the volume of the subcallosal area and total behavioral scores. A regression analysis with CDR score and TMT-B time as a confounders
revealed a significant association between the volume of the subcallosal area and the total behavioral score (β = −0.32, p = 0.002).
disorders and the reduction of integrity of this specific tract
has been found to associate with disinhibition (26, 42, 46,
47) and aberrant motor behavior (28). Our results support
previous findings and also suggest that damage to this specific
area associates with frequency and severity of disinhibition
and aberrant motor behavior, regardless of the underlying
etiology of neurodegeneration. This information could be of great
value, considering possible symptom specific treatments such
as transcranial magnetic stimulation (TMS), similarly as used
in psychiatric conditions for therapeutic purposes. Yet, more
studies with larger cohorts and with different diseases are needed
to validate these results.
Strengths and Weaknesses
The patients were clinically well-examined by a neurologist
specialized in memory disorders and diagnosed according
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FIGURE 4 | Correlation of the total and individual behavioral symptoms with brain volumes. In the first row, total behavioral symptom scores show a correlation with
the subcallosal area and left superior frontal gyrus. All three symptom scores show a correlation with ventromedial prefrontal cortex. The left superior frontal gyrus
showed a correlation with elation and disinhibition, while aberrant motor behavior was associated with right superior frontal gyrus. In addition to frontal volumes,
disinhibition scores were associated with the bilateral temporal pole. The subcallosal area is shown in cyan circle in the top row. Irritability and agitation showed no
correlation with any focal brain volume. Negative correlations are shown in red. No positive correlations were detected.
to recent clinical guidelines for MCI, AD, and bvFTD.
As limitations, we did not have healthy controls with a
neuropsychiatric evaluation, thus the study population consisted
only of subjects with subjective and/or evident clinical symptoms.
By contrary, this is the first study where neuropsychiatric
symptoms and neuroanatomical correlations has been evaluated
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with MCI cases with very mild cognitive symptoms. Our study
setting was cross-sectional, meaning variability in frequency
and severity of neuropsychiatric symptoms and brain volumes
between diseases represents the differences only at the time
of clinical diagnosis. In future studies we emphasize the
importance of longitudinal assessment of atrophy rate and
behavioral symptoms. We also performed a similar regression
analysis with different diagnostic groups separately and the
associations (β-values) between neuropsychiatric symptoms and
frontal volumes were similar to those performed with the whole
cohort. However, due to the small sample sizes of each diagnostic
group, our analyses were unpowered, and the results did not
reach statistical significance. Also, we needed to focus on frontal
lobes, since due to small sample size whole brain analyses
would have been unpowered. The MRI scans were obtained
with a homogenous protocol and segmented with a reliable and
validated multi-atlas method. The scans were performed with
different scanners, however the segmentation method has been
shown to be relatively robust over different scanner models.
The results did not survive correction for multiple testing
(Bonferroni correction). However, we set the threshold for
statistical significance at p ≤ 0.005 for associations of frontal
volumes and behavioral symptoms and p ≤ 0.001 for differences
in frontal brain volumes between groups in order to maintain
reliability of the results.
CONCLUSIONS
Our findings show that behavioral symptoms in
neurodegenerative dementing diseases are associated with
atrophy of specific frontal cortical areas and associations appear
to be independent of disease etiology and cognitive performance.
Especially, the subcallosal area was found to associate well with
the behavioral symptoms regardless of clinical diagnosis, thus
damage to this area may be a common neuroanatomical area for
behavioral symptoms in neurodegenerative diseases independent
of the specific type of dementia.
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